Evidence map›Paper›PMID 42382559›Full record

ArticleProstate international2026

A proposal for integrating intraductal carcinoma of the prostate into pathological T substaging.

Remi Semba, Katsunori Uchida, Takeshi Sasaki, Takahiro Inoue, Hiroshi Miyamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Remi SembaDepartment of Pathology, Kuwana City Medical Center, Mie, Japan.
Katsunori UchidaDepartment of Pathology, Kansai Medical University, Osaka, Japan.
Takeshi SasakiDepartment of Nephro-urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan.
Takahiro InoueDepartment of Nephro-urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan.
Hiroshi MiyamotoDepartments of Pathology & Laboratory Medicine and Urology, University of Rochester Medical Center, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The present study aims primarily to determine how incorporation of intraductal carcinoma of the prostate (IDCP) detected in radical prostatectomy (RP) specimens into pathological T (pT) impacts patient outcomes. Methods: The study included 1,190 patients who had undergone RP at Mie University Hospital (Tsu, Mie, Japan) from 2015 to 2023 ( Results: The prognosis of the pT2/IDCP group was significantly better than that of the other groups ( Conclusions: IDCP in pT2 and pT3a cases was strongly associated with the risk of BCR. In addition, the prognosis for pT2/IDCP + versus pT3a/IDCP- or pT3b/IDCP- versus pT3b/IDCP+ was comparable. These findings indicate that IDCP may confer a BCR risk comparable to that of extraprostatic extension in pT2 cases but its prognostic impact appears limited in pT3b disease.

Indexed as

Intraductal carcinoma of the prostatePathological T substagingProstate cancer

Identifiers

PMID42382559
PMCPMC13316393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.